Company news

Abeona Therapeutics Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Abeona Therapeutics® Completes Pz-cel Biologics License Application Resubmission to U.S. Food and Drug Administration

October 28, 2024

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 30, 2024

Abeona Therapeutics® Announces Appointment of Bernhardt Zeiher, MD, FCCP, FACP, and Eric Crombez, MD to its Board of Directors

August 13, 2024

Abeona Therapeutics® Announces Favorable Medicare Reimbursement Decisions for Pz-cel

August 12, 2024

Abeona Therapeutics® Reports Second Quarter 2024 Financial Results and Concludes Type A Meeting with FDA to Align on Upcoming Pz-cel BLA Resubmission

August 11, 2024

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 31, 2024

Abeona Therapeutics and Beacon Therapeutics Announce Non-Exclusive Agreement for Beacon to Evaluate Therapeutic Potential of Abeona's Patented AAV204 Capsid for Select Ophthalmology Indications

July 10, 2024

Abeona Therapeutics to Present at the Stifel Virtual Cell Therapy Forum

July 7, 2024

Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 2, 2024

Abeona Therapeutics to Present at the Jefferies Global Healthcare Conference

May 27, 2024

Abeona Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Progress

May 14, 2024

Abeona Therapeutics Announces Pricing of $75 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

May 2, 2024

Abeona Therapeutics Provides Regulatory Update on Pz-cel

April 21, 2024

Abeona Therapeutics Reports Full Year 2023 Financial Results and Announces Completion of FDA Inspections

March 17, 2024

Abeona Therapeutics Announces Progress Update on Pz-cel Biologics License Application (BLA)

January 31, 2024

Abeona Therapeutics Announces $50 Million Credit Facility

January 7, 2024

Abeona Therapeutics Announces FDA Accepts and Grants Priority Review for Pz-cel Biologics License Application (BLA)

November 26, 2023

Abeona Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Developments

November 12, 2023

Abeona Therapeutics Submits Biologics License Application to U.S. FDA Seeking Priority Review and Approval of EB-101 for the Treatment of Patients with Recessive Dystrophic Epidermolysis Bullosa

September 25, 2023

Abeona Therapeutics Appoints Madhav Vasanthavada, Ph.D., M.B.A. as Chief Commercial Officer

September 11, 2023

Abeona Therapeutics Announces Participation in Upcoming Investor Conferences

September 6, 2023

Abeona Therapeutics Announces Positive Pre-BLA Meeting with FDA for EB-101 and Plans for BLA Submission

August 29, 2023

Abeona Therapeutics Reports Second Quarter 2023 Financial Results

August 7, 2023

Abeona Therapeutics Announces Submission of Briefing Package for Pre-Biologics License Application (BLA) Meeting with FDA in August 2023

July 27, 2023

Abeona Therapeutics Joins Rare Disease Company Coalition

July 18, 2023

Abeona Therapeutics Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

July 2, 2023

Abeona Therapeutics Announces Regulatory Update on Biologics License Application (BLA) for EB-101

June 8, 2023

Abeona Therapeutics to Present at the Jefferies Healthcare Conference

May 31, 2023

Abeona Therapeutics Announces Date Change for First Quarter 2023 Portfolio Update Conference Call to May 24, 2023

May 21, 2023

Abeona Therapeutics Announces New Preclinical Data from its AAV Ophthalmology Program at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

May 15, 2023

Abeona Therapeutics Reports First Quarter 2023 Financial Results

May 10, 2023

Abeona Therapeutics Announces Additional Phase 3 VIITAL™ Study Results for EB-101 Presented at the International Societies for Investigative Dermatology 2023 Meeting

May 10, 2023

Abeona Therapeutics Announces Multiple Abstracts Accepted from its AAV Ophthalmology Program at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

April 9, 2023

Abeona Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update

March 28, 2023

Abeona Therapeutics Announces New Employee Inducement Grants

March 23, 2023

Abeona Therapeutics Announces Acceptance of Abstract on EB-101 Phase 3 VIITAL™ Study Results for Oral Presentation at International Societies for Investigative Dermatology (ISID) 2023 Meeting

March 15, 2023

Abeona Therapeutics Announces Update on AAV Ophthalmology Program

March 13, 2023

Abeona Therapeutics Reports Third Quarter 2022 Financial Results

November 13, 2022

Abeona Therapeutics Announces Positive Topline Results with Both Co-Primary Endpoints Met in Pivotal Phase 3 VIITAL™ Study of EB-101

November 2, 2022

Abeona Therapeutics Announces $35 Million Private Placement Financing

November 2, 2022

Abeona Therapeutics Announces Database Lock for Pivotal Phase 3 VIITAL™ Study of EB-101 in Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB)

October 18, 2022

Abeona Therapeutics Announces Completion of Patient Follow-up in Pivotal Phase 3 VIITAL™ Study of EB-101 in Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB)

October 3, 2022

Abeona Therapeutics to Participate in the Jefferies Cell and Genetic Medicine Summit

September 21, 2022

Abeona Therapeutics to Participate in the Cantor Fitzgerald Cell and Genetic Medicines Conference

September 12, 2022

Abeona Therapeutics Reports Second Quarter 2022 Financial Results

August 10, 2022

Abeona Therapeutics Regains Compliance with Nasdaq Listing Requirements

July 19, 2022

Abeona Therapeutics Granted Second 180-Day Period by Nasdaq to Regain Compliance with Minimum Bid Price Rule

May 18, 2022

Ultragenyx Acquires Global Rights to AAV Gene Therapy ABO-102 for Sanfilippo Syndrome Type A (MPS IIIA) from Abeona Therapeutics

May 16, 2022

Abeona Therapeutics Reports First Quarter 2022 Financial Results

May 12, 2022

Abeona Therapeutics Announces AAV204, a Novel AAV Capsid, Demonstrated Robust Macular Transduction Following Para-Retinal Administration in Non-Human Primates

May 3, 2022

← Newer news releases · Older news releases →

Calls

The 5 newest of 19 calls. Every call is listed under its year.

Decks

The 5 newest of 18 decks. Every deck is listed under its year.